- GlobalData CEO sells £22.5 million shares
- Everyman director Rosehill ups stake
- Bioventix CEO sells £2.6 million shares
Michael Danson, CEO of GlobalData (DATA:AIM), a London-based data analytics and consulting company has sold 11,194,030 shares at 201p for a total value of £22.5 million on 31 January.
Non-executive director Peter Harkness has sold 235,700 shares at 201p for a total value of £473,731 on the same day.
The sell off comes after the data analytics and consulting company reported a strong trading update several weeks ago.
These directors could be cashing in on a strong share price. GlobalData shares are up 13% over the past year to 200p.
The AIM-listed firm said it anticipated achieving full-year group revenue of £273 million – 12% annual growth compared to £243 million in 2022.
On 21 December GlobalData also unveiled a new growth plan and a strategic group reorganisation into ‘three customer-focussed divisions.’
Michael Rosehill, non-executive director of premium cinema operator Everyman Media (EMAN:AIM) and director of private equity firm Blue Coast has bought 3,75 million shares at 56p for a total value of £2.1 million on 1 February.
Following this transaction Blue Coast’s total holding has risen to 25,083,639 ordinary shares, equating to 28.3% of the company’s issued capital.
Rosehill’s move is not a surprise as he has been quietly building up his stake in the premium cinema operator since last year.
On 22 November, Rosehill bought in total 900,000 shares for approximately £507,000.
Shares in Everyman are down 18% over the past year and Rosehill could be partaking in a spot of bargain-hunting.
BIOVENTIX CEO SELLS UP
Peter Harrison CEO of Bioventix (BVXP:AIM), a high affinity monoclinal antibodies developer and supplier, has sold 62,000 shares at £42 for a total value of £2.6 million on 29 January.
The sale was facilitated to enable a new institutional investor to join the share register.
Harrison has undertaken not to dispose of any further ordinary shares for 12 months.
Following the sale, Harrison has a beneficial interest in 297,088 ordinary shares, representing approximately 5.7% of the issued share capital of the company.
Bioventix recently reported a positive set of results for the year ending 30 June, with pre-tax profits up 9% to £10.1 million.
The firm said at the time there were plenty of research projects in the pipeline which will ‘create additional shareholder value in the later 2020s and 2030s.’
Year-to-date the shares are up 4%.
